CNS Drug Design: Balancing Physicochemical Propertie

Journal of Medicinal Chemistry
58, 2584-2608
DOI: 10.1021/jm501535r

Citation Report

#	Article	IF	Citations
1	A Versatile Approach to CF₃â€Containing 2â€Pyrrolidones by Tandem Michael Additionâ€“Cyclization: Exemplification in the Synthesis of Amidine Class BACE1 Inhibitors. Chemistry - A European Journal, 2015, 21, 11719-11726.	1.7	16
2	A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets. Frontiers in Neurology, 2015, 6, 197.	1.1	22
3	Biomolecular recognition of antagonists by Î±7 nicotinic acetylcholine receptor: Antagonistic mechanism and structureâ€“activity relationships studies. European Journal of Pharmaceutical Sciences, 2015, 76, 119-132.	1.9	5
4	Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment. Future Medicinal Chemistry, 2015, 7, 2411-2413.	1.1	6
5	Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signalling, 2015, 11, 371-387.	1.1	45
6	Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis. ACS Medicinal Chemistry Letters, 2015, 6, 913-918.	1.3	35
7	Methyl-substitution of an iminohydantoin spiropiperidine Î²-secretase (BACE-1) inhibitor has a profound effect on its potency. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4812-4819.	1.0	17
8	Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2015, 58, 5942-5949.	2.9	17
9	Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 6733-6746.	2.9	35
10	Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 2015, 6, 947-955.	3.5	15
11	Exploring cinnamic acid scaffold: development of promising neuroprotective lipophilic antioxidants. MedChemComm, 2015, 6, 1043-1053.	3.5	25
12	Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochemical Pharmacology, 2015, 98, 587-601.	2.0	15
13	Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu₅ Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). Journal of Medicinal Chemistry, 2015, 58, 6653-6664.	2.9	150
14	Structureâ€“Affinity Relationship Analysis of Selective FKBP51 Ligands. Journal of Medicinal Chemistry, 2015, 58, 7796-7806.	2.9	32
15	Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 8200-8215.	2.9	113
16	Molecular determinants of bloodâ€“brain barrier permeation. Therapeutic Delivery, 2015, 6, 961-971.	1.2	89
17	Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy Î¼ Opioid Receptor/Î´ Opioid Receptor Ligands. ACS Chemical Neuroscience, 2015, 6, 1428-1435.	1.7	26
18	Tuning the predictive capacity of the PAMPA-BBB model. European Journal of Pharmaceutical Sciences, 2015, 79, 53-60.	1.9	32

#	Article	IF	Citations
19	1,4-Oxazine Î²-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. Journal of Medicinal Chemistry, 2015, 58, 8216-8235.	2.9	67
20	Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies. Frontiers in Neuroscience, 2016, 10, 265.	1.4	62
21	CNS Multiparameter Optimization Approach: Is it in Accordance with Occamâ€™s Razor Principle?. Molecular Informatics, 2016, 35, 94-98.	1.4	7
22	The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR. ACS Symposium Series, 2016, , 147-173.	0.5	3
23	Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Scientific Reports, 2016, 6, 39495.	1.6	105
24	In vitro bloodâ€“brain barrier permeability predictions for GABAA receptor modulating piperine analogs. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 103, 118-126.	2.0	35
25	Discovery of the first A₁ adenosine receptor ligand based on the chromone scaffold. RSC Advances, 2016, 6, 46972-46976.	1.7	4
26	Evolution of physicochemical properties of melanin concentrating hormone receptor 1 (MCHr1) antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4559-4564.	1.0	7
27	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 8967-9004.	2.9	71
28	Synthesis and Biological Evaluation ofN-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1. Journal of Medicinal Chemistry, 2016, 59, 8473-8494.	2.9	12
29	Assessment of the classification abilities of the CNS multi-parametric optimization approach by the method of logistic regression. SAR and QSAR in Environmental Research, 2016, 27, 629-635.	1.0	2
30	Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors. Tetrahedron, 2016, 72, 6127-6135.	1.0	8
31	A BOILEDâ€Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem, 2016, 11, 1117-1121.	1.6	1,249
32	Temozolomide analogs with improved brain/plasma ratios â€“ Exploring the possibility of enhancing the therapeutic index of temozolomide. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5103-5109.	1.0	12
33	Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4403-4407.	1.0	18
34	Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Bloodâ€“Brain Barrier Model. Molecular Pharmaceutics, 2016, 13, 3341-3349.	2.3	36
35	Discovery and Structureâ€“Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2016, 59, 7683-7689.	2.9	115
36	Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry, 2016, 59, 10030-10066.	2.9	106

#	Article	IF	Citations
37	Structural and Physico-Chemical Interpretation (SPCI) of QSAR Models and Its Comparison with Matched Molecular Pair Analysis. Journal of Chemical Information and Modeling, 2016, 56, 1455-1469.	2.5	35
38	Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11Î²-Hydroxysteroid Dehydrogenase Type 1 (11Î²-HSD1). Journal of Medicinal Chemistry, 2016, 59, 10176-10189.	2.9	18
39	Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents. Journal of Medicinal Chemistry, 2016, 59, 6791-6806.	2.9	76
40	Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structureâ€“Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives. Journal of Medicinal Chemistry, 2016, 59, 1116-1139.	2.9	17
41	Physicochemical property profile for brain permeability: comparative study by different approaches. Journal of Drug Targeting, 2016, 24, 655-662.	2.1	7
42	Validation of an immortalized human (hBMEC) in vitro blood-brain barrier model. Analytical and Bioanalytical Chemistry, 2016, 408, 2095-2107.	1.9	29
43	Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery. ACS Chemical Neuroscience, 2016, 7, 767-775.	1.7	338
44	Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System. Molecular Pharmaceutics, 2016, 13, 1540-1550.	2.3	36
45	Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinsonâ€™s disease. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 103, 62-70.	2.0	8
46	Development of a Novel Nonpeptidic ¹⁸F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	2.9	17
47	Retinoid-related orphan receptor gamma t (RORÎ³t) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742. Expert Opinion on Therapeutic Patents, 2016, 26, 737-744.	2.4	34
48	A new PAMPA model using an in-house brain lipid extract for screening the bloodâ€“brain barrier permeability of drug candidates. International Journal of Pharmaceutics, 2016, 501, 102-111.	2.6	41
49	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. Chemical Research in Toxicology, 2016, 29, 564-616.	1.7	148
50	Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs. ACS Medicinal Chemistry Letters, 2016, 7, 89-93.	1.3	37
51	A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinsonâ€™s Disease Using RapidFire Mass Spectrometry. Journal of Biomolecular Screening, 2016, 21, 145-155.	2.6	35
52	Assessing molecular scaffolds for CNS drug discovery. Drug Discovery Today, 2017, 22, 965-969.	3.2	37
53	Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2017, 60, 1272-1291.	2.9	31
54	Approaches for the discovery of novel positron emission tomography radiotracers for brain imaging. Clinical and Translational Imaging, 2017, 5, 265-274.	1.1	5

#	Article	IF	Citations
55	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 â€“Part I. Expert Opinion on Therapeutic Patents, 2017, 27, 733-751.	2.4	36
56	The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. Journal of Medicinal Chemistry, 2017, 60, 3552-3579.	2.9	212
57	Therapeutic implications of tumor interstitial acidification. Seminars in Cancer Biology, 2017, 43, 119-133.	4.3	82
58	1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. Journal of Medicinal Chemistry, 2017, 60, 5663-5672.	2.9	27
59	Radiosynthesis of (S)-[18 F] T1 : The first PET radioligand for molecular imaging of Î±3Î²4 nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2017, 124, 106-113.	0.7	6
60	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2239-2258.	1.0	19
61	Sustainable Practices in Medicinal Chemistry Part 2: Green by Design. Journal of Medicinal Chemistry, 2017, 60, 5955-5968.	2.9	17
62	CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. Journal of Medicinal Chemistry, 2017, 60, 5943-5954.	2.9	75
63	Small-Molecule Inhibitors of LRRK2. Advances in Neurobiology, 2017, 14, 241-264.	1.3	29
65	Binary Classification of CNS and PNS Drugs. Pharmaceutical Chemistry Journal, 2017, 50, 800-804.	0.3	0
66	Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 127, 250-262.	2.6	95
67	Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. ACS Medicinal Chemistry Letters, 2017, 8, 151-156.	1.3	35
68	Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences. Journal of Medicinal Chemistry, 2017, 60, 9807-9820.	2.9	7
69	Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker. Journal of Medicinal Chemistry, 2017, 60, 9360-9375.	2.9	11
70	Interpretation of Quantitative Structureâ€“Activity Relationship Models: Past, Present, and Future. Journal of Chemical Information and Modeling, 2017, 57, 2618-2639.	2.5	168
71	Synthesis and Determination of Lipophilicity, Anticonvulsant Activity, and Preliminary Safety of 3â€Substituted and 3â€Unsubstituted Nâ€[(4â€Arylpiperazinâ€1â€yl)alkyl]pyrrolidineâ€2,5â€dione Derivatives. ChemMedChem, 2017, 12, 1848-1856.	3.6	7
72	Therapeutic Approaches to Prion Diseases. Progress in Molecular Biology and Translational Science, 2017, 150, 433-453.	0.9	8
73	Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. Progress in Medicinal Chemistry, 2017, 56, 37-80.	4.1	17

#	Article	IF	Citations
74	Discovery of a Tetrahydrobenzisoxazole Series of Î³-Secretase Modulators. ACS Medicinal Chemistry Letters, 2017, 8, 1002-1006.	1.3	9
75	Novel Vilazodoneâ€“Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimerâ€™s Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. ACS Chemical Neuroscience, 2017, 8, 2708-2721.	1.7	32
76	A Smallâ€Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity. ChemMedChem, 2017, 12, 1286-1292.	1.6	5
77	Time-sequenced drug delivery approaches towards effective chemotherapeutic treatment of glioma. Materials Horizons, 2017, 4, 977-996.	6.4	14
78	Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery. Chemical Communications, 2017, 53, 12345-12348.	2.2	15
79	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. Journal of Medicinal Chemistry, 2017, 60, 6897-6910.	2.9	20
80	Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. Journal of Medicinal Chemistry, 2017, 60, 6273-6288.	2.9	19
81	Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rheinâ€“huprine hybrids. Future Medicinal Chemistry, 2017, 9, 965-981.	1.1	40
82	Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization. ACS Chemical Neuroscience, 2017, 8, 147-154.	1.7	30
83	RORÎ³t inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert Opinion on Therapeutic Patents, 2017, 27, 1-8.	2.4	45
84	MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 109-113.	1.0	3
85	Tactics for preclinical validation of receptor-binding radiotracers. Nuclear Medicine and Biology, 2017, 44, 4-30.	0.3	18
86	N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimerâ€™s agents. Bioorganic and Medicinal Chemistry, 2017, 25, 633-645.	1.4	49
87	Discovery of SHR9352: A Highly Potent G Protein-Biased Î¼-Opioid Receptor Agonist. ACS Omega, 2017, 2, 9261-9267.	1.6	10
88	Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. , 2017, , 259-277.		4
89	Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects. Current Medicinal Chemistry, 2017, 24, 3921-3937.	1.2	4
90	Pathobiology and Therapeutic Implications of Tumor Acidosis. Current Medicinal Chemistry, 2017, 24, 2827-2845.	1.2	10
91	Inhibiting Kinases in the CNS. , 2017, , 408-446.		0

#	Article	IF	Citations
92	From Imaging Agents to Theranostic Drugs in Alzheimerâ€™s Disease. , 2017, , 74-106.		1
93	Understanding brain penetrance of anticancer drugs. Neuro-Oncology, 2018, 20, 589-596.	0.6	12
94	Drug Distribution into Peripheral Nerve. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 336-345.	1.3	27
95	Current Challenges and Opportunities in Treating Glioblastoma. Pharmacological Reviews, 2018, 70, 412-445.	7.1	571
96	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. Neurotherapeutics, 2018, 15, 742-750.	2.1	5
97	Furoxans (Oxadiazole-4N-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory. Journal of Medicinal Chemistry, 2018, 61, 4593-4607.	2.9	17
98	Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. Drug Metabolism and Disposition, 2018, 46, 658-666.	1.7	24
99	Design, Synthesis, and Evaluation of Orally Bioavailable Quinolineâ€“Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2018, 61, 1871-1894.	2.9	70
100	Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro-Oncology, 2018, 20, 307-312.	0.6	29
101	Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1981-1991.	1.0	18
102	Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. Dalton Transactions, 2018, 47, 7190-7205.	1.6	30
103	Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems. Drug Discovery Today, 2018, 23, 1357-1372.	3.2	52
104	Syntheses and inÂvitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents. European Journal of Medicinal Chemistry, 2018, 150, 796-808.	2.6	15
105	The Literature of Heterocyclic Chemistry, Part XV, 2015. Advances in Heterocyclic Chemistry, 2018, , 121-173.	0.9	6
106	Expanding LogP: Present possibilities. Nuclear Medicine and Biology, 2018, 58, 20-32.	0.3	17
107	A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in glioblastoma therapy. European Journal of Medicinal Chemistry, 2018, 144, 1-28.	2.6	40
108	The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 119-139.	2.9	112
109	Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chemical Neuroscience, 2018, 9, 587-602.	1.7	9

#	Article	IF	Citations
110	Nose to Brain Drug Delivery: A Recent Update. Journal of Formulation Science & Bioavailability, 2018, 01, .	0.0	2
111	Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). Journal of Medicinal Chemistry, 2018, 61, 11021-11036.	2.9	100
112	Optimization of 8-Hydroxyquinolines as Inhibitors of CatecholO-Methyltransferase. Journal of Medicinal Chemistry, 2018, 61, 9647-9665.	2.9	18
113	Contribution assessment of multiparameter optimization descriptors in CNS penetration. SAR and QSAR in Environmental Research, 2018, 29, 785-800.	1.0	5
114	A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications, 2018, 9, 4399.	5.8	65
115	Impact of Payload Hydrophobicity on the Stability of Antibodyâ€“Drug Conjugates. Molecular Pharmaceutics, 2018, 15, 2656-2664.	2.3	61
116	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine Î²-Secretase (BACE1) Inhibitors via Active Conformation Stabilization. Journal of Medicinal Chemistry, 2018, 61, 5525-5546.	2.9	28
117	Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7503-7524.	2.9	12
118	Tau-Centric Multitarget Approach for Alzheimerâ€™s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3Î² and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7640-7656.	2.9	81
119	MetStabOnâ€”Online Platform for Metabolic Stability Predictions. International Journal of Molecular Sciences, 2018, 19, 1040.	1.8	24
120	Drug Disposition Considerations in Pharmaceutical Product. , 2018, , 337-369.		2
121	Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities. European Journal of Medicinal Chemistry, 2018, 156, 598-617.	2.6	72
122	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. Journal of Medicinal Chemistry, 2018, 61, 10345-10374.	2.9	67
123	Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2. ACS Chemical Neuroscience, 2018, 9, 3108-3116.	1.7	64
124	Hydroxybenzoic Acid Derivatives as Dual-Target Ligands: Mitochondriotropic Antioxidants and Cholinesterase Inhibitors. Frontiers in Chemistry, 2018, 6, 126.	1.8	32
125	A perspective on multiâ€target drug discovery and design for complex diseases. Clinical and Translational Medicine, 2018, 7, 3.	1.7	481
126	Rational Design of Novel 1,3-Oxazine Based Î²-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust AÎ² Reduction in the Brain. Journal of Medicinal Chemistry, 2018, 61, 5122-5137.	2.9	29
127	Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1â€“Nuclear Factor Erythroid 2-Related Factor 2 (Keap1â€“Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases. Journal of Medicinal Chemistry, 2018, 61, 8088-8103.	2.9	71

#	Article	IF	Citations
128	Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A2B receptor. Bioorganic and Medicinal Chemistry, 2018, 26, 4650-4663.	1.4	17
129	Traversal of the Bloodâ€“Brain Barrier by Cleavable <scp>l</scp>-Lysine Conjugates of Apigenin. Journal of Agricultural and Food Chemistry, 2018, 66, 8124-8131.	2.4	8
130	Novel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 182, 111596.	2.6	12
131	Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study. MedChemComm, 2019, 10, 1892-1899.	3.5	3
132	Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chemical Reviews, 2019, 119, 10520-10594.	23.0	499
133	Challenging the CNS Targeting Potential of Systemically Administered Nanoemulsion Delivery Systems: a Case Study with Rapamycin-Containing Fish Oil Nanoemulsions in Mice. Pharmaceutical Research, 2019, 36, 134.	1.7	7
134	Advances in the Physicochemical Profiling of Opioid Compounds of Therapeutic Interest. ChemistryOpen, 2019, 8, 879-887.	0.9	16
135	Antifungal Drugs: Special Problems Treating Central Nervous System Infections. Journal of Fungi (Basel, Switzerland), 2019, 5, 97.	1.5	20
136	WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimerâ€™s Disease and Modulates Cerebral Î²-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration. ACS Chemical Neuroscience, 2019, 10, 4787-4799.	1.7	8
137	Practical approaches to evaluating and optimizing brain exposure in early drug discovery. European Journal of Medicinal Chemistry, 2019, 182, 111643.	2.6	15
138	Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis. Pharmaceutics, 2019, 11, 446.	2.0	21
139	Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na_V1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy. Journal of Medicinal Chemistry, 2019, 62, 9618-9641.	2.9	21
140	Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIÎ± inhibiting anticancer agent. Computational Biology and Chemistry, 2019, 79, 73-82.	1.1	38
141	Predicting Bloodâ€“Brain Barrier Permeability of Marine-Derived Kinase Inhibitors Using Ensemble Classifiers Reveals Potential Hits for Neurodegenerative Disorders. Marine Drugs, 2019, 17, 81.	2.2	29
142	Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice. Drug Metabolism and Disposition, 2019, 47, 393-404.	1.7	38
143	Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 2019, 1, 612-624.	4.4	46
144	UHPLC-HRMS study of anti-Alzheimerâ€™s drug candidates: metabolism of 7-MEOTA-tryptophan hybrids hampers their passage into brain. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 134-144.	1.4	2
145	Phytoâ€Tacrine Hybrids as Promising Drugs to Treat Alzheimer's Disease. ChemistrySelect, 2019, 4, 5776-5790.	0.7	5

#	Article	IF	Citations
146	Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors. Cancers, 2019, 11, 824.	1.7	43
147	Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2294-2301.	1.0	39
148	2-Deoxyglycosylation towards more effective and bioavailable neuroprotective molecules inspired by nature. Pure and Applied Chemistry, 2019, 91, 1209-1221.	0.9	5
149	Developments with multi-target drugs for Alzheimerâ€™s disease: an overview of the current discovery approaches. Expert Opinion on Drug Discovery, 2019, 14, 879-891.	2.5	60
150	Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as antiâ€Alzheimer's agents. Archiv Der Pharmazie, 2019, 352, e1800352.	2.1	15
151	Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Bloodâ€“Brain Barrier Penetration. ACS Medicinal Chemistry Letters, 2019, 10, 996-1001.	1.3	9
152	Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. International Journal of Pharmaceutics, 2019, 565, 258-268.	2.6	124
153	Discovery of 2-phenoxyacetamides as inhibitors of the Wnt-depalmitoleating enzyme NOTUM from an X-ray fragment screen. MedChemComm, 2019, 10, 1361-1369.	3.5	22
154	Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents. European Journal of Medicinal Chemistry, 2019, 174, 116-129.	2.6	35
155	Rivastigmine and metabolite analogues with putative Alzheimerâ€™s disease-modifying properties in a Caenorhabditis elegans model. Communications Chemistry, 2019, 2, .	2.0	25
156	Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome. Drug Discovery Today, 2019, 24, 1166-1175.	3.2	7
157	Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntingtonâ€™s Disease Models. Journal of Medicinal Chemistry, 2019, 62, 2988-3008.	2.9	14
158	Bifunctional opioid receptor ligands as novel analgesics. Neuropharmacology, 2019, 151, 195-207.	2.0	34
159	Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. Drug Metabolism and Disposition, 2019, 47, 665-672.	1.7	31
160	Synthesis, in vivo anticonvulsant testing, and molecular modeling studies of new nafimidone derivatives. Drug Development Research, 2019, 80, 606-616.	1.4	20
161	Optimization of Bloodâ€“Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. Journal of Medicinal Chemistry, 2019, 62, 2690-2707.	2.9	29
162	Pharmaceutical Considerations for Treatment of the Central Nervous System. , 2019, , 859-863.		0
163	IVIVC Assessment of Two Mouse Brain Endothelial Cell Models for Drug Screening. Pharmaceutics, 2019, 11, 587.	2.0	20

#	Article	IF	Citations
164	An improved, scalable synthesis of Notum inhibitor LP-922056 using 1-chloro-1,2-benziodoxol-3-one as a superior electrophilic chlorinating agent. Beilstein Journal of Organic Chemistry, 2019, 15, 2790-2797.	1.3	10
165	Exploring anticancer activity of structurally modified benzylphenoxyacetamide (BPA); I: Synthesis strategies and computational analyses of substituted BPA variants with high anti-glioblastoma potential. Scientific Reports, 2019, 9, 17021.	1.6	4
166	Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules, 2019, 24, 4217.	1.7	18
167	A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy. Molecules, 2019, 24, 4197.	1.7	17
168	In vitroandin silicodetermination of glutaminyl cyclase inhibitors. RSC Advances, 2019, 9, 29619-29627.	1.7	14
169	Drug Concentration Asymmetry in Tissues and Plasma for Small Moleculeâ€“Related Therapeutic Modalities. Drug Metabolism and Disposition, 2019, 47, 1122-1135.	1.7	79
170	Allosteric Activation of Striatal-Enriched Protein Tyrosine Phosphatase (STEP, PTPN5) by a Fragment-like Molecule. Journal of Medicinal Chemistry, 2019, 62, 306-316.	2.9	29
171	Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2019, 27, 931-943.	1.4	29
172	Pharmacokinetics and brain distribution of amitraz and its metabolites in rats. Environmental Toxicology and Pharmacology, 2019, 65, 40-45.	2.0	5
173	6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M₁ mAChR: The Determinants of Allosteric Activity. ACS Chemical Neuroscience, 2019, 10, 1099-1114.	1.7	7
174	Synthesis, bioactivity and molecular modeling studies on potential anti-Alzheimer piperidinehydrazide-hydrazones. Bioorganic Chemistry, 2019, 87, 888-900.	2.0	18
175	Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 83-88.	1.0	30
176	Brain imaging with near-infrared fluorophores. Coordination Chemistry Reviews, 2019, 380, 550-571.	9.5	68
177	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals, 2019, 12, 7.	1.7	9
178	Comparison between Polybutylcyanoacrylate Nanoparticles with Either Surface-Adsorbed or Encapsulated Brain-Derived Neurotrophic Factor on the Neural Differentiation of iPSCs. International Journal of Molecular Sciences, 2019, 20, 182.	1.8	11
179	Tacrine hybrids as multi-target-directed ligands in Alzheimerâ€™s disease: influence of chemical structures on biological activities. Chemical Papers, 2019, 73, 269-289.	1.0	44
180	Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. European Journal of Medicinal Chemistry, 2019, 161, 292-309.	2.6	41
181	Structureâ€“Activity Relationships of Central Nervous System Penetration by Fatty Acid Amide Hydrolase (FAAH)-Targeted Thyromimetic Prodrugs. ACS Medicinal Chemistry Letters, 2019, 10, 111-116.	1.3	10

#	Article	IF	Citations
182	Plasma Protein Binding of Highly Bound Drugs Determined With Equilibrium Gel Filtration of Nonradiolabeled Compounds and LC-MS/MS Detection. Journal of Pharmaceutical Sciences, 2019, 108, 1053-1060.	1.6	17
183	Development of a novel progesterone analog in the treatment of traumatic brain injury. Neuropharmacology, 2019, 145, 292-298.	2.0	9
184	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 451-489.	3.3	86
185	Stem Cell Extracellular Vesicles and their Potential to Contribute to the Repair of Damaged CNS Cells. Journal of NeuroImmune Pharmacology, 2020, 15, 520-537.	2.1	24
186	Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability. Journal of Pharmaceutical Sciences, 2020, 109, 161-168.	1.6	28
187	Influence of transporters in treating cancers in the CNS. , 2020, , 277-301.		2
188	Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent Notum inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126751.	1.0	13
189	Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models. Journal of Medicinal Chemistry, 2020, 63, 1032-1050.	2.9	21
190	Theoretical molecular predictions and antimicrobial activities of newly synthesized molecular hybrids of norfloxacin and ciprofloxacin. Journal of Heterocyclic Chemistry, 2020, 57, 225-237.	1.4	9
191	Synthesis of Pyridoclax Analogues: Insight into Their Druggability by Investigating Their Physicochemical Properties and Interactions with Membranes. ChemMedChem, 2020, 15, 136-154.	1.6	4
193	Structure-Based Scaffold Repurposing toward the Discovery of Novel Cholinesterase Inhibitors. ACS Omega, 2020, 5, 30971-30979.	1.6	6
194	Combining Machine Learning and Molecular Dynamics to Predict P-Glycoprotein Substrates. Journal of Chemical Information and Modeling, 2020, 60, 4730-4749.	2.5	30
195	Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. Journal of Medicinal Chemistry, 2020, 63, 10061-10085.	2.9	12
196	Perspectives for New and More Efficient Multifunctional Ligands for Alzheimerâ€²s Disease Therapy. Molecules, 2020, 25, 3337.	1.7	31
197	The Critical Role of Passive Permeability in Designing Successful Drugs. ChemMedChem, 2020, 15, 1862-1874.	1.6	53
198	Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity. Journal of Medicinal Chemistry, 2020, 63, 9464-9483.	2.9	12
199	Probing simple structural modification of Î±â€mangostin on its cholinesterase inhibition and cytotoxicity. Archiv Der Pharmazie, 2020, 353, e2000156.	2.1	9
200	Bloodâ€“brain barrier: mechanisms governing permeability and interaction with peripherally acting Î¼-opioid receptor antagonists. Regional Anesthesia and Pain Medicine, 2020, 45, 688-695.	1.1	18

#	Article	IF	Citations
201	Aminotriazines with indole motif as novel, 5-HT7 receptor ligands with atypical binding mode. Bioorganic Chemistry, 2020, 104, 104254.	2.0	7
202	5-Phenyl-1,3,4-oxadiazol-2(3H)-ones Are Potent Inhibitors of Notum Carboxylesterase Activity Identified by the Optimization of a Crystallographic Fragment Screening Hit. Journal of Medicinal Chemistry, 2020, 63, 12942-12956.	2.9	13
203	One Pot Synthesis of Micromolar BACE-1 Inhibitors Based on the Dihydropyrimidinone Scaffold and Their Thia and Imino Analogues. Molecules, 2020, 25, 4152.	1.7	14
204	Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy Âμ opioid receptor agonist and a Î´ opioid receptor antagonist. Psychopharmacology, 2020, 237, 3591-3602.	1.5	5
205	Microglia-targeting nanotherapeutics for neurodegenerative diseases. APL Bioengineering, 2020, 4, 030902.	3.3	49
206	PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives. Molecules, 2020, 25, 4017.	1.7	6
207	Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. Journal of Medicinal Chemistry, 2020, 63, 4978-4996.	2.9	15
208	SG1002 and Catenated Divalent Organic Sulfur Compounds as Promising Hydrogen Sulfide Prodrugs. Antioxidants and Redox Signaling, 2020, 33, 1010-1045.	2.5	28
209	Discovery of Novel Imidazopyridine GSK-3Î² Inhibitors Supported by Computational Approaches. Molecules, 2020, 25, 2163.	1.7	14
210	Synthesis and Structureâ€“Activity Relationships of 5â€²-Aryl-14-alkoxypyridomorphinans: Identification of a Î¼ Opioid Receptor Agonist/Î´ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. Journal of Medicinal Chemistry, 2020, 63, 7663-7694.	2.9	21
211	Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. Pharmacological Reviews, 2020, 72, 668-691.	7.1	6
212	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathologica Communications, 2020, 8, 78.	2.4	28
213	From combinations to multitargetâ€directed ligands: A continuum in Alzheimer's disease polypharmacology. Medicinal Research Reviews, 2021, 41, 2606-2633.	5.0	88
214	Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes. Pharmaceutics, 2020, 12, 417.	2.0	17
215	Substrate Specific Inhibitor Designed against the Immunomodulator GMF-beta Reversed the Experimental Autoimmune Encephalomyelitis. Scientific Reports, 2020, 10, 3790.	1.6	5
216	In vivo Characterization of Four 18F-Labeled S1PR1 Tracers for Neuroinflammation. Molecular Imaging and Biology, 2020, 22, 1362-1369.	1.3	13
217	Triggering the Antitumor Activity of Acyclic Enediyne through Maleimide-Assisted Rearrangement and Cycloaromatization. Journal of Organic Chemistry, 2020, 85, 9808-9819.	1.7	19
218	Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). European Journal of Medicinal Chemistry, 2020, 191, 112149.	2.6	4

#	Article	IF	Citations
219	Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127053.	1.0	7
220	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 275-286.	2.4	29
221	Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity. ACS Medicinal Chemistry Letters, 2020, 11, 127-132.	1.3	9
222	Most Influential Physicochemical and In Vitro Assay Descriptors for Hepatotoxicity and Nephrotoxicity Prediction. Chemical Research in Toxicology, 2020, 33, 1780-1790.	1.7	3
223	Pharmaceutical applications of organofluorine compounds. , 2020, , 133-214.		0
224	Synthesis and evaluation of NLRP3-inhibitory sulfonylurea [11C]MCC950 in healthy animals. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127186.	1.0	14
225	Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. Brain Research Bulletin, 2020, 160, 121-140.	1.4	72
226	N-alkylpiperidine carbamates as potential anti-Alzheimerâ€™s agents. European Journal of Medicinal Chemistry, 2020, 197, 112282.	2.6	33
227	First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate. Journal of Medicinal Chemistry, 2020, 63, 4528-4554.	2.9	14
228	Developing new treatments in partnership for primary mitochondrial disease: What does industry need from academics, and what do academics need from industry?. Journal of Inherited Metabolic Disease, 2021, 44, 301-311.	1.7	2
229	Preclinical Comparison of the Bloodâ€“brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clinical Cancer Research, 2021, 27, 189-201.	3.2	106
230	Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases. Journal of Huntington's Disease, 2021, 10, 203-220.	0.9	21
231	Brain penetrating peptides and peptideâ€“drug conjugates to overcome the bloodâ€“brain barrier and target <scp>CNS</scp> diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1695.	3.3	90
232	Central Nervous System Multiparameter Optimization Desirability. , 2021, , 1-8.		0
233	Ligand- and Structure-Based Analysis of Deep Learning-Generated Potential Î±2a Adrenoceptor Agonists. Journal of Chemical Information and Modeling, 2021, 61, 481-492.	2.5	1
234	Synthesis, Molecular Docking, BSA, and In Vitro Reactivation Study of Imidazopyridine Oximes Against Paraoxon Inhibited Acetylcholinesterase. Medicinal Chemistry, 2022, 18, 273-287.	0.7	6
235	Hydrazones of 4-(Trifluoromethyl)benzohydrazide as New Inhibitors of Acetyl- and Butyrylcholinesterase. Molecules, 2021, 26, 989.	1.7	15
236	Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based Î²-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. Journal of Medicinal Chemistry, 2021, 64, 1873-1888.	2.9	30

#	Article	IF	Citations
237	Drug penetration in pediatric brain tumors: Challenges and opportunities. Pediatric Blood and Cancer, 2021, 68, e28983.	0.8	10
238	Quinuclidine-Based Carbamates as Potential CNS Active Compounds. Pharmaceutics, 2021, 13, 420.	2.0	7
239	Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntingtonâ€™s Disease. Journal of Medicinal Chemistry, 2021, 64, 5018-5036.	2.9	7
240	Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of ¹¹C-Labeled ALK2 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 846-850.	1.3	5
242	Modern approaches to the development of synthetic cannabinoid receptor probes. Pharmacology Biochemistry and Behavior, 2021, 203, 173119.	1.3	8
243	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central AÎ² reduction. European Journal of Medicinal Chemistry, 2021, 216, 113270.	2.6	7
244	Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity. Pharmaceuticals, 2021, 14, 485.	1.7	1
245	A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids. Drugs - Real World Outcomes, 2021, 8, 393-406.	0.7	3
246	Rational Design of Novel Therapies for Pantothenate <scp>Kinaseâ€“Associated</scp> Neurodegeneration. Movement Disorders, 2021, 36, 2005-2016.	2.2	12
247	Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model. AAPS Journal, 2021, 23, 72.	2.2	7
248	Enhancing Target Tissue Levels and Diminishing Plasma Clearance of Ionizing Zwitterionic Antidotes in Organophosphate Exposures. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 315-321.	1.3	2
249	Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios. AAPS Journal, 2021, 23, 81.	2.2	18
250	A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. Nano Letters, 2021, 21, 5158-5166.	4.5	14
251	Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. ACS Medicinal Chemistry Letters, 2021, 12, 1130-1136.	1.3	12
252	Cheminformatic Characterization of Natural Antimicrobial Products for the Development of New Lead Compounds. Molecules, 2021, 26, 3970.	1.7	11
253	Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives. International Journal of Molecular Sciences, 2021, 22, 6442.	1.8	38
254	In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis. ACS Omega, 2021, 6, 14748-14764.	1.6	2
256	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction. European Journal of Medicinal Chemistry, 2021, 218, 113383.	2.6	13

#	Article	IF	Citations
257	Developability profile framework for lead candidate selection in topical dermatology. International Journal of Pharmaceutics, 2021, 604, 120750.	2.6	3
258	Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. Journal of Medicinal Chemistry, 2021, 64, 9786-9874.	2.9	29
259	Oat polyphenol avenanthramide-2c confers protection from oxidative stress by regulating the Nrf2-ARE signaling pathway in PC12Âcells. Archives of Biochemistry and Biophysics, 2021, 706, 108857.	1.4	15
260	Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain. Bioorganic and Medicinal Chemistry, 2021, 42, 116245.	1.4	8
261	Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl Moiety. Journal of Medicinal Chemistry, 2021, 64, 11014-11044.	2.9	18
262	Chemical and Structural Strategies to Selectively Target mTOR Kinase. ChemMedChem, 2021, 16, 2744-2759.	1.6	12
263	Strategies for Structural Modification of Small Molecules to Improve Bloodâ€“Brain Barrier Penetration: A Recent Perspective. Journal of Medicinal Chemistry, 2021, 64, 13152-13173.	2.9	69
264	Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems. Pharmaceutics, 2021, 13, 1542.	2.0	18
265	Navigating into the Chemical Space of Monoamine Oxidase Inhibitors by Artificial Intelligence and Cheminformatics Approach. ACS Omega, 2021, 6, 23399-23411.	1.6	11
266	How can SHAP values help to shape metabolic stability of chemical compounds?. Journal of Cheminformatics, 2021, 13, 74.	2.8	36
267	Ensemble modeling with machine learning and deep learning to provide interpretable generalized rules for classifying CNS drugs with high prediction power. Briefings in Bioinformatics, 2022, 23, .	3.2	21
269	Design, synthesis and biological evaluation of naphthalene-derived (arylalkyl)azoles containing heterocyclic linkers as new anticonvulsants: A comprehensive in silico, in vitro, and in vivo study. European Journal of Pharmaceutical Sciences, 2021, 166, 105974.	1.9	10
270	Identification of dual inhibitor of phosphodiesterase 1B/10A using structure-based drug design approach. Journal of Molecular Liquids, 2021, 342, 117485.	2.3	5
271	N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 226, 113817.	2.6	4
272	Drug Efflux Transporters: P-gp and BCRP. RSC Drug Discovery Series, 2021, , 109-127.	0.2	0
273	Occurrence of Morpholine in Central Nervous System Drug Discovery. ACS Chemical Neuroscience, 2021, 12, 378-390.	1.7	30
274	Application and assessment of deep learning for the generation of potential NMDA receptor antagonists. Physical Chemistry Chemical Physics, 2021, 23, 1197-1214.	1.3	9
275	Synthesis of morpholine derivatives using the Castagnoli-Cushman reaction as BACE1 inhibitors: Unexpected binding activity of cyclic thioamides. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127211.	1.0	4

#	Article	IF	Citations
276	A Perspective on Multi-target Drugs for Alzheimerâ€™s Disease. Trends in Pharmacological Sciences, 2020, 41, 434-445.	4.0	148
277	Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists. ACS Chemical Neuroscience, 2017, 8, 2290-2308.	1.7	10
278	Huprines â€" an insight into the synthesis and biological properties. Russian Chemical Reviews, 2020, 89, 999-1039.	2.5	6
279	Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death. JCI Insight, 2017, 2, .	2.3	26
280	Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging. Current Medicinal Chemistry, 2016, 23, 1818-1869.	1.2	149
281	The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications. Current Medicinal Chemistry, 2020, 27, 1515-1561.	1.2	2
282	Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems. Current Medicinal Chemistry, 2020, 27, 599-629.	1.2	11
283	Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders. Current Pharmaceutical Design, 2020, 26, 594-619.	0.9	17
284	Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 801-814.	0.7	5
285	Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors. Current Topics in Medicinal Chemistry, 2020, 20, 2106-2117.	1.0	9
286	Development of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes - Part 2. Bioorganic and Medicinal Chemistry Letters, 2021, 53, 128416.	1.0	0
287	Binary classification of blood-brain barrier penetration by the logistic regression method. Biomedical Chemistry Research and Methods, 2018, 1, e00065.	0.1	0
288	Hydrogen Bond Contribution to Drug Bioavailability: cheminformatics approach. Biomedical Chemistry Research and Methods, 2018, 1, e00060.	0.1	1
290	Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 211-219.	2.0	5
291	Mechanisms Involved in Microglial-Interceded Alzheimerâ€™s Disease and Nanocarrier-Based Treatment Approaches. Journal of Personalized Medicine, 2021, 11, 1116.	1.1	9
292	Potential of Ramalin and Its Derivatives for the Treatment of Alzheimerâ€™s Disease. Molecules, 2021, 26, 6445.	1.7	2
293	Back to the Medicinal Chemistry Future. Journal of Medicinal Chemistry, 2021, 64, 15515-15518.	2.9	2
294	Solubilization of Progesterone and its Derivatives into Gemini Surfactant Solutions. Journal of Oleo Science, 2020, 69, 557-562.	0.6	4

#	Article	IF	Citations
295	Multi-objective optimization methods in novel drug design. Expert Opinion on Drug Discovery, 2021, 16, 647-658.	2.5	23
296	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa151.	0.4	1
297	In vitro antineurodegenerative activity and in silico predictions of blood-brain barrier penetration of Helichrysum plicatum flower extract. Lekovite Sirovine, 2020, , 45-51.	0.8	4
299	Design, synthesis and structure-activity evaluation of novel 2-pyridone-based inhibitors of Î±-synuclein aggregation with potentially improved BBB permeability. Bioorganic Chemistry, 2021, 117, 105472.	2.0	11
303	Proposition of Potential GSK-3Î² Inhibitors for the Treatment of Alzheimerâ€™s Disease: A Molecular Modeling Study. Current Computer-Aided Drug Design, 2020, 16, 541-554.	0.8	0
305	BACE1: A Key Regulator in Alzheimerâ€™s Disease Progression and Current Development of its Inhibitors. Current Neuropharmacology, 2022, 20, 1174-1193.	1.4	12
306	Radiosynthesis and evaluation of a fluorine-18 radiotracer [¹⁸F]FS1P1 for imaging sphingosine-1-phosphate receptor 1. Organic and Biomolecular Chemistry, 2022, 20, 1041-1052.	1.5	5
307	Targeting brain metastases in breast cancer. Cancer Treatment Reviews, 2022, 103, 102324.	3.4	46
308	An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry. Biomedicine and Pharmacotherapy, 2022, 146, 112549.	2.5	2
309	Human Blood-Brain-Barrier In Vitro Models: Overview and Applications. Handbook of Experimental Pharmacology, 2021, , 205-222.	0.9	1
310	Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Journal of Cannabis Research, 2022, 4, 2.	1.5	6
311	Firstâ€inâ€class pyrido[2,3â€•d]pyrimidineâ€2,4(1 H ,3 H)â€diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights. Archiv Der Pharmazie, 2022, , e2100440.	2.1	4
312	Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. Bioorganic and Medicinal Chemistry, 2022, 56, 116614.	1.4	44
313	Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist. ACS Medicinal Chemistry Letters, 2022, 13, 457-462.	1.3	18
314	A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 377-387.	1.3	10
315	The Therapeutic Prospects of Targeting IL-1R1 for the Modulation of Neuroinflammation in Central Nervous System Disorders. International Journal of Molecular Sciences, 2022, 23, 1731.	1.8	14
316	Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis. Journal of Experimental Pharmacology, 2022, Volume 14, 43-57.	1.5	5
317	Fluoroalkylation of Dextromethorphan Improves CNS Exposure and Metabolic Stability. ACS Medicinal Chemistry Letters, 2022, 13, 707-713.	1.3	4

#	Article	IF	Citations
318	Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration. Scientific Reports, 2022, 12, 3384.	1.6	5
319	Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. Journal of Medicinal Chemistry, 2022, 65, 5095-5112.	2.9	6
320	Design of a Stable Coamorphous System Using Lactose as an Antiplasticizing Agent for Diphenhydramine Hydrochloride with a Low Glass Transition Temperature. Molecular Pharmaceutics, 2022, 19, 1209-1218.	2.3	5
321	Optimization of a Pyrimidinone Series for Selective Inhibition of Ca²⁺/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain. Journal of Medicinal Chemistry, 2022, 65, 4667-4686.	2.9	3
322	Discovery of novel donepezil-M30D hybrids with neuroprotective properties for Alzheimerâ€™s disease treatment. Medicinal Chemistry Research, 2022, 31, 867-885.	1.1	3
324	Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy. European Journal of Medicinal Chemistry, 2022, 233, 114242.	2.6	14
325	A computational study of somatostatin subtype-4 receptor agonist binding. SN Applied Sciences, 2022, 4, 1.	1.5	2
326	A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines. Neuro-Oncology Advances, 2022, 4, vdab192.	0.4	0
327	Prediction of Blood-Brain Barrier Penetration (BBBP) Based on Molecular Descriptors of the Free-Form and In-Blood-Form Datasets. Molecules, 2021, 26, 7428.	1.7	6
328	Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 13085.	1.8	10
329	Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brainâ€”a Game Changing Parameter for CNS Drug Discovery and Development. Pharmaceutical Research, 2022, 39, 1321-1341.	1.7	31
330	Natural Products from Plants and Algae for Treatment of Alzheimerâ€™s Disease: A Review. Biomolecules, 2022, 12, 694.	1.8	12
331	Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 8345-8379.	2.9	3
332	Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structureâ€“Activity Relationships Insights and Evolution Prospects. Journal of Medicinal Chemistry, 2022, 65, 7016-7043.	2.9	10
333	Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain. European Journal of Medicinal Chemistry, 2022, 237, 114413.	2.6	5
334	Synthesis, Biological Evaluation, and Docking Studies of Antagonistic Hydroxylated Arecaidine Esters Targeting mAChRs. Molecules, 2022, 27, 3173.	1.7	4
337	Central Nervous System Multiparameter Optimization Desirability. , 2022, , 242-249.		0
338	Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities. Progress in Medicinal Chemistry, 2022, , 1-91.	4.1	7

#	Article	IF	Citations
339	Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy. Journal of the American Chemical Society, 2022, 144, 12367-12380.	6.6	6
340	2-Aminopyridines with a shortened amino sidechain as potent, selective, and highly permeable human neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 69, 116878.	1.4	6
341	Rational Design and Optimization of m⁶A-RNA Demethylase FTO Inhibitors as Anticancer Agents. Journal of Medicinal Chemistry, 2022, 65, 10920-10937.	2.9	23
342	Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer. Journal of Molecular Modeling, 2022, 28, .	0.8	1
343	Discovery of novel neuroprotective cinnamoyl-M30D hybrids targeting Alzheimerâ€™s disease. Medicinal Chemistry Research, 2022, 31, 1974-1989.	1.1	0
344	Novel Multipotent Amantadineâ€“M30D Hybrids with Highly Selective Butyrylcholinesterase Inhibition and Neuroprotective Effects as Effective Anti-Alzheimerâ€™s Agents. ACS Chemical Neuroscience, 2022, 13, 2681-2698.	1.7	1
345	Brain-restricted mTOR inhibition with binary pharmacology. Nature, 2022, 609, 822-828.	13.7	27
347	Generation of new inhibitors of selected cytochrome P450 subtypesâ€“ In silico study. Computational and Structural Biotechnology Journal, 2022, 20, 5639-5651.	1.9	2
348	Design, Synthesis and Biological Evaluation of Biscarbamates as Potential Selective Butyrylcholinesterase Inhibitors for the Treatment of Alzheimerâ€™s Disease. Pharmaceuticals, 2022, 15, 1220.	1.7	3
349	Relief of <scp>CoA</scp> sequestration and restoration of mitochondrial function in a mouse model of propionic acidemia. Journal of Inherited Metabolic Disease, 2023, 46, 28-42.	1.7	7
350	Hydrogen-Bond Donors in Drug Design. Journal of Medicinal Chemistry, 2022, 65, 14261-14275.	2.9	39
353	A Review of the Recent Advances in Alzheimerâ€™s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics, 2022, 12, 2975.	1.3	5
354	Artificial Neural Network Models Driven Novel Virtual Screening Workflow for the Identification and Biological Evaluation of BACE1 Inhibitors.. Molecular Informatics, 0, , .	1.4	2
355	Current Update on Transcellular Brain Drug Delivery. Pharmaceutics, 2022, 14, 2719.	2.0	7
356	Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
357	Structural Alterations of the â€œAddressâ€•Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity. Journal of Medicinal Chemistry, 2023, 66, 577-595.	2.9	5
358	Recent Development of Hybrids and Derivatives of Resveratrol in Neurodegenerative Diseases. , 2022, , 27-72.		0
359	Nâ€Substituted piperidineâ€3â€carbohydrazideâ€hydrazones against Alzheimer's disease: Synthesis and evaluation of cholinesterase, betaâ€amyloid inhibitory activity, and antioxidant capacity. Archiv Der Pharmazie, 2023, 356, .	2.1	1

#	Article	IF	Citations
360	A Quantum Mechanics-Based Method to Predict Intramolecular Hydrogen Bond Formation Reflecting P-glycoprotein Recognition. ACS Medicinal Chemistry Letters, 0, , .	1.3	0
361	High-content phenotypic screen to identify small molecule enhancers of Parkin-dependent ubiquitination and mitophagy. SLAS Discovery, 2023, 28, 73-87.	1.4	4
362	â€˜Chemistry at the speed of soundâ€™: automated 1536-well nanoscale synthesis of 16 scaffolds in parallel. Green Chemistry, 2023, 25, 1380-1394.	4.6	7
363	Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter. Journal of Medicinal Chemistry, 2023, 66, 371-383.	2.9	2
364	Advances in Antibody-Based Therapeutics for Cerebral Ischemia. Pharmaceutics, 2023, 15, 145.	2.0	1
365	Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity. European Journal of Medicinal Chemistry, 2023, 251, 115132.	2.6	0
366	Synthesis and studies of new purines/pyrimidine derivatives as multi-targeted agents involving various receptor sites in the immune system. Molecular Diversity, 2024, 28, 97-110.	2.1	0
367	Strategies for designing novel positron emission tomography (PET) radiotracers to cross the bloodâ€“brain barrier. Journal of Labelled Compounds and Radiopharmaceuticals, 2023, 66, 205-221.	0.5	6
368	Toxic profile of marinobufagin from poisonous Amazon toads and antitumoral effects on human colorectal carcinomas. Journal of Ethnopharmacology, 2023, 310, 116406.	2.0	2
369	Studies on diketopiperazine and dipeptide analogs as opioid receptor ligands. European Journal of Medicinal Chemistry, 2023, 254, 115309.	2.6	4
370	Designing of 2,3-dihydrobenzofuran derivatives as inhibitors of PDE1B using pharmacophore screening, ensemble docking and molecular dynamics approach. Computers in Biology and Medicine, 2023, 159, 106869.	3.9	2
371	Novel S1R agonists counteracting NMDA excitotoxicity and oxidative stress: A step forward in the discovery of neuroprotective agents. European Journal of Medicinal Chemistry, 2023, 249, 115163.	2.6	5
372	Discovery of a Series of Substituted 1H-((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators. Journal of Medicinal Chemistry, 2023, 66, 2877-2892.	2.9	1
373	Evaluation of advanced, pathophysiologic new targets for imaging of CNS. Drug Development Research, 2023, 84, 418-447.	1.4	3
374	Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2081-2099.	3.3	1
396	Anesthetic drug discovery with computer-aided drug design and machine learning. , 2024, 2, .		0
397	Intrathecal Chemotherapy for Central Nervous System Malignancy. , 2023, , 567-582.		0
401	Essential Considerations for Brain Delivery of Nanoformulations. , 2023, , 251-269.		0

#	Article	IF	Citations